Oxford Cannabinoid
Technologies Holdings plc
("OCT" or the
"Company")
Total Voting
Rights
In accordance with the Financial
Conduct Authority's (FCA) Disclosure Guidance and Transparency Rule
5.6.1, Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP)
confirms that as of 29 February 2024, its issued share capital
consists of 1,088,415,644 ordinary shares of 0.1 pence each,
(Ordinary Shares), each with one voting right. The Company does not
hold any shares in treasury. Therefore, the total number of voting
rights on 29 February 2024 is, 1,088,415,644.
This figure should be used by
shareholders as the denominator for calculations by which they can
determine if they are required to notify their interest in, or a
change to their interest in, the Company under the FCA's Disclosure
Guidance and Transparency Rules.
The Directors of the Company take
responsibility for this announcement.
Enquiries:
|
Oxford Cannabinoid Technologies Holdings plc
|
+44 (0)20 3034 2820
|
|
Clarissa Sowemimo-Coker
(CEO)
|
clarissa@oxcantech.com
|
|
|
|
|
Cairn Financial Advisers LLP
|
|
|
Emily Staples
|
+44 (0)20 7213 0897
|
|
Jo Turner
|
+44 (0) 20 7213 0885
|
|
|
|
|
Axis
Capital Markets Limited
|
|
|
Richard Hutchison
|
+44 (0)20 3026 0320
|
|
|
|
|
Acuitas Communications
|
020 3745 0293 / 07799
767676
|
|
Simon Nayyar
|
simon.nayyar@acuitascomms.com
|
|
Arthur Dingemans
|
arthur.dingemans@acuitascomms.com
|
About Oxford Cannabinoid Technologies Holdings
Plc:
OCT is the holding company
of Oxford Cannabinoid Technologies Ltd and OCT Victoria Pty
Ltd (together the "Group"), a pharmaceutical Group developing
prescription cannabinoid medicines initially targeting the US$
multi-billion global pain market.
OCT currently has a portfolio of
four drug development programmes. Its lead compound, OCT461201,
will initially target neuropathic and visceral pain (including
irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN"). The global market for CIPN
alone is currently forecast to reach US$1.17bn by 2028.
OCT's drug development pipeline
comprises both natural and synthetic compounds, and includes
compounds targeting trigeminal neuralgia, a severe type of face
pain, and cannabinoid derivatives targeting pain and
potentially other therapeutic areas. Having established an
exclusive licence agreement with Canopy Growth Corporation for
their entire pharmaceutical cannabinoid derivative library, OCT now
has a portfolio of almost five hundred derivatives and intellectual
property rights including fourteen patent families and associated
research data.
OCT has a clearly defined path to
commercialisation, revenues and growth. The Group is developing
drug candidates through clinical trials to gain regulatory approval
(FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCT's portfolio aims to balance risk, value
and time to market, whilst ensuring market exclusivity around all
its key activities.
